Here's a list of the current breast cancer clinical trials and collaborations with drug companies from the cancer center at Goshen Cancer Center (a center referred to in Biocurex archives as being in collaboration with the company):Treatment Trials / Breast Cancer
NSABP B-35: A clinical trial comparing Anastrozole with Tamoxifen, taken for five years, in postmenopausal women with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy. This double-blind study will evaluate the effectiveness in preventing the subsequent occurrence of breast cancer.
CTSU/ECOG/SWOG S0012: A clinical trial to compare response rates in patients with inflammatory and locally advanced breast cancer treated with weekly Doxorubicin and daily oral Cyclophosphamide given with G-CSF support followed by weekly Paclitaxel for 12-weeks, to that in patients treated with the standard Doxorubicin and Cyclophosphamide regimen given every 3 weeks by Paclitaxel for 12-weeks.
NSABP B-36: A clinical trial of adjuvant therapy comparing 6 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to 4 cycles of Adriamycin and Cyclophosphamide (AC) with or without Celecoxib with node-negative breast cancer. The primary aim is to determine if one regimen is superior in prolonging disease free survival.
NSABP B-38: The primary aim of this study for women with node-positive breast cancer are to determine whether a regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel and gemcitabine (DD AC→PG) will be superior to a regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) as well as to a regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel alone (DD AC→P) in improving disease-free survival (DFS) and to compare the relative DFS of TAC and DD AC→P.
INTERNAL CCC BRE 0-6710: Mammary Ductoscopy and Intraductal Biopsy for Women at High Risk for Developing Breast Cancer – A Post Market Registry
INTERNAL CCC BRE 0-6711: Mammary Ductoscopy and Intraductal Biopsy for Women Presented with Spontaneous Nipple Discharge – A Post Market Registry
CTSU/ECOG/NCIC MA-27: A randomized Phase III Trial of Exemestane versus Anastrozole with or without Celecoxib in Postmenopausal Women with Receptor Positive Pimary Breast Cancer. Adjuvant chemotherapy and radiation are allowable. Treatment is for 5 years.
Scouty |
AI
